Relation between body mass index, forced expiratory volume in one second and 6 minute walk test in stable COPD patients

Bhaskar Kakarla; Rajendra Prasad Boddula; Paramjyothi Gongati

doi:10.18203/2320-6012.ijrms20163992

Authors

Bhaskar Kakarla Department of Respiratory Medicine, Nizams Institute of Medical Sciences, Hyderabad, Telangana, India
Rajendra Prasad Boddula Department of Respiratory Medicine, Nizams Institute of Medical Sciences, Hyderabad, Telangana, India
Paramjyothi Gongati Department of Respiratory Medicine, Nizams Institute of Medical Sciences, Hyderabad, Telangana, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20163992

Keywords:

Body mass index, COPD, FEV1, 6 Minute walk test

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is a common respiratory disorder characterized by irreversible, progressive airflow obstruction. It is diagnosed by spirometry which measures FEV1 and bronchoreversibility. Recent focus has been on COPD systemic effects like malnutrition, cardiovascular disorders, diabetes, musculoskeletal disorders, anxiety and depression. A composite index named BODE index (BMI, FEV1, dyspnea, 6MWT) has a better prediction of mortality than FEV1 alone in these patients. Relation between components of BODE like BMI, FEV1 and 6MWT has been an area of interest since it measures nutritional status (BMI), airway obstruction (FEV1) and exercise capacity (6MWT). We tried to evaluate the relation between lower BMI (˂21) and higher BMI groups (>21) with respect to FEV1 and 6MWT.

Methods: A cross sectional observation study was conducted in a tertiary care centre. Stable patients of COPD were recruited from to outpatient department of respiratory medicine. BMI, FEV1 and 6MWT were calculated. Patients are made into 2 groups with BMI less than 21 and more than 21. Both FEV1 and 6MWT means were calculated and analyzed to find out any difference between these two groups.

Results: There was no statistical difference of FEV1 and 6MWT between lower and higher BMI groups.

Conclusions: In COPD patients, FEV1 and 6MWT values were not statistically different between lower and higher BMI groups. Further studies are needed to prove that other anthropometric measurement like fat free mass index can be a better substitute for more accurate assessment of exercise capacity.

Metrics

Metrics Loading ...

References

WHO. Household air pollution and health. 2016.

Amaral AF, Coton S, Kato B, Tan WC, Studnicka M, Janson C, Gislason T, Mannino D, Bateman ED, Buist S, Burney PG. BOLD Collaborative Research Group. Tuberculosis associates with both airflow obstruction and low lung function: BOLD Results. Eur Respir J. 2015;46(4):1104-12.

WHO. World health statistics. 2008.

Stang P, Lydick E, Silberman C, Kempel A, Keating ET. The prevalence of COPD: using smoking rates to estimate disease frequency in the general population. Chest. 2000;117(5):354-9.

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available at http:// www.goldcopd.it/ materiale/2015/GOLD_Pocket_2015 .pdf. Accessed on 12 July 2016.

Decramer M, Benedetto DF, Ponte DA, Marinari S. Systemic effects of COPD. Respir Med. 2005;99:3-10.

Laforest L, Roche N, Devouassoux G, Belhassen M, Chouaid C, Ginoux M, Van GE. Frequency of comorbidities in chronic obstructive pulmonary disease, and impact on all-cause mortality: A population-based cohort study. Respir Med. 2016;117:33-9.

Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM, Hanania NA. ACCP workshop panel on anxiety and depression in COPD. Anxiety and depression in COPD: current understanding, unanswered questions and research needs. Chest. 2008;134(4):43-56.

Sanders KJ, Kneppers AE, Bool VC, Langen RC, Schols AM. Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective. J Cachexia Sarcopenia Muscle. 2016;7(1):5-22.

Manen JG, Bindels PJ, Ijzermans CJ, Zee JS, Bottema BJ, Schadé E. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol. 2001;54(3):287-93.

Jo YS, Choi SM, Lee J, Park YS, Lee SM, Yim JJ, Yoo CG, Kim YW, Han SK, Lee CH. The relationship between chronic obstructive pulmonary disease and comorbidities: a cross-sectional study using data from KNHANES 2010-2012. Respir Med. 2015;109(1):96-104.

Gologanu D, Ionita D, Gartonea T, Stanescu C, Bogdan MA. Body composition in patients with chronic obstructive pulmonary disease. Maedica (Buchar). 2014;9(1):25-32.

De S. Body mass index among patient with chronic obstructive pulmonary diseases. Indian J Physiology Pharmacology. 2012;56(4):353-8.

Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Singer TR. Evaluation of COPD longitudinally to identify surrogate endpoints (ECLIPSE) study investigators. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res. 2011;12:146.

Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity and tissue repair and destruction. Eur Respir J. 2008;31(6):1334-56.

Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J. 2006;28(1):219-42.

Núnez B, Sauleda J, Anto JM, Julia MR, Orozco M, Monsó E, Noguera A, Gómez FP, Aymerich GJ, Agusti A. PAC-COPD investigators anti-tissue antibodies are related to lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;15;183(8):1025-31.

Mac NW. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann Med. 2013;45(3):291-300.

Tsuji T, Aoshiba K, Nagai A. Cigarette smoke induces senescence in alveolar epithelial cells. Am J Respir Cell Mol Biol. 2004;31(6):643-9.

Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:95-9.

Oga T, Tsukino M, Hajiro T, Ikeda A, Nishimura K. Analysis of longitudinal changes in dyspnea of patients with chronic obstructive pulmonary disease: an observational study. Respir Res. 2012;25(13):85.

Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto PV, Cabral HJ. The body-mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005-12.

Ko FW, Tam W, Tung AH, Ngai J, Ng SS, Lai K, Au KF, Hui DS. A longitudinal study of serial BODE indices in predicting mortality and readmissions for COPD. Respir Med. 2011 Feb;105(2):266-73.

Hodgev VA, Kostianev SS, Marinov BA. Correlation of frequency of exacerbations with the BODE index in COPD patients. Folia Med (Plovdiv). 2006;48(2):18-22.

Casanova C, Torres JP, Aguirre JA, Pinto PV, Marin JM, Cordoba E, Baz R, Cote C, Celli BR. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med. 2011;184(9):1015-21.

Motegi T, Jones RC, Ishii T, Hattori K, Kusunoki Y, Furutate R, Yamada K, Gemma A, Kida K. A comparison of three multidimensional indices of COPD severity as predictors of future exacerbations. Int J Chron Obstruct Pulmon Dis. 2013;8:259-71.

Menezes AM, Jardim JR, Padilla PR, Camelier A, Rosa F, Nascimento O, Hallal PC. Prevalence of chronic obstructive pulmonary disease and associated factors: the PLATINO Study in São Paulo, Brazil. Cad Saude Publica. 2005;21(5):1565-73.

Khan RI, Fleg JL, Wise RA. Body mass index and the risk of COPD. Chest. 2002;121(2):370-6.

Cao C, Wang R, Wang J, Bunjhoo H, Xu Y, Xiong W. Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS One. 2012;7(8):43892.

Guo, Yibin. Body mass index and mortality in chronic obstructive pulmonary disease: a dose response meta-analysis. Medicine. 2016;95:28.

Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(6):1856-61.

Zhou Y, Wang D, Liu S, Lu J, Zheng J, Zhong N, Ran P. The association between BMI and COPD: the results of two population-based studies in Guangzhou, China. COPD. 2013;10(5):567-72.

Schols AM, Broekhuizen R, Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr. 2005;82(1):53-9.

Hronek M, Kovarik M, Aimova P, Koblizek V, Pavlikova L, Salajka F, Zadak Z. Skinfold anthropometry the accurate method for fat free mass measurement in COPD. COPD. 2013 Oct;10(5):597-603.

Pothirat C, Chaiwong W, Phetsuk N, Liwsrisakun C, Bumroongkit C, Deesomchok A, Theerakittikul T, Limsukon A. The relationship between body composition and clinical parameters in chronic obstructive pulmonary disease. J Med Assoc Thai. 2016;99(4):386-93.

ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-7.

Jenkins, Sue C. 6-minute walk test in patients with COPD: clinical applications in pulmonary rehabilitation. Physiotherapy. 2007;93:175-82.

Spruit MA, Watkins ML, Edwards LD, Vestbo J, Calverley PM, Plata PV, Celli BR, Singer TR, Wouters EF. Evaluation of COPD longitudinally to identify predictive surrogate endpoints (eclipse) study investigators. determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med. 2010;104(6):849-57.

Ischaki E, Papatheodorou G, Gaki E, Papa I, Koulouris N, Loukides S. Body mass and fat-free mass indices in COPD: relation with variables expressing disease severity. Chest. 2007;132(1):164-9.

Fujimoto H, Asai K, Watanabe T, Kanazawa H, Hirata K. Association of six-minute walk distance (6MWD) with resting pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Osaka City Med J. 2011;57(1):21-9.